Prosecution Insights
Prosecution Insights
2 pending office actions • 0 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
BIOTHEUS INC. is currently managing 2 pending office actions. These matters are distributed among 2 distinct examiners, showing that each pending action is being reviewed by a different individual within the patent office. This distribution requires the company to manage separate prosecution tracks for its current applications.
LU, CHENG is the busiest examiner for the portfolio, holding 1 busiest examiner pending action. This indicates that 1 of the 2 pending office actions is handled by LU, CHENG, while the other is assigned to a different official. The company must address the unique requirements of 2 distinct examiners to advance its current matters, as the workload is distributed across multiple individuals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LU, CHENG | 1 | 54.1% | +64.1% |
| HAM, JIEUN | 1 | 50.0% | +8.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18702317 | ANTI-MESOTHELIN NANOBODIES AND USE THEREOF | LU, CHENG | — |
| 18684551 | BISPECIFIC ANTIBODY AND USE THEREOF | HAM, JIEUN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18702317 | ANTI-MESOTHELIN NANOBODIES AND USE THEREOF | LU, CHENG | — | §102§112 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18684551 | BISPECIFIC ANTIBODY AND USE THEREOF | HAM, JIEUN | — | §102§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial